Phase 1 Multicenter, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Response of PE0139 Injection in Adult Subjects With Type 2 Diabetes Mellitus

NCT01835730 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

37

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes Mellitus (T2DM)

Interventions

DRUG: PE0139 Injection
DRUG: Placebo

Sponsor

PhaseBio Pharmaceuticals Inc.